Assessing the Patient Experience of Hypoparathyroidism Symptoms: Development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom).
Journal
The patient
ISSN: 1178-1661
Titre abrégé: Patient
Pays: New Zealand
ID NLM: 101309314
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
26
9
2019
medline:
7
4
2021
entrez:
26
9
2019
Statut:
ppublish
Résumé
Hypoparathyroidism is a rare endocrine disorder characterized by absent or inappropriately low levels of circulating parathyroid hormone. Patients with hypoparathyroidism receiving standard-of-care therapy report debilitating physical and cognitive symptoms, which may indicate a reduced health-related quality of life. The purpose of this study was to develop a new disease-specific measure of the signs and symptoms of hypoparathyroidism, the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom), and provide evidence for the content validity of items in the measure based on rigorous qualitative research methodologies for patient-reported outcome development. Semi-structured, individual concept elicitation interviews were conducted with five clinical experts and 42 adults with hypoparathyroidism in the USA to identify the signs and symptoms of relevance and importance to those with the condition. Transcripts were coded and analyzed using an adapted grounded theory approach. Following item generation, cognitive debriefing interviews of the draft measure were conducted in an independent sample of 16 adults with hypoparathyroidism. One hundred percent of the concept elicitation patient sample reported experiencing physical symptoms that were attributed to hypoparathyroidism, including tingling/numbness/paresthesia (n = 37, 88%), muscle cramping (n = 36, 86%), and physical fatigue (n = 35, 83%). The majority of patients (n = 36, 86%) further reported experiencing cognitive dysfunction, including impaired memory (n = 24, 57%), impaired ability to have a conversation (n = 21, 50%), and lack of concentration/focus (n = 18, 43%). Seventeen major signs and symptoms were identified during item generation and included in the preliminary measure. After the cognitive debriefing, the 17-item HPES-Symptom was generated. The findings provided evidence of content validity for the HPES-Symptom in US adults with hypoparathyroidism. Additional research is needed to validate the measure in patients with hypoparathyroidism to assess its psychometric properties.
Sections du résumé
BACKGROUND AND OBJECTIVE
Hypoparathyroidism is a rare endocrine disorder characterized by absent or inappropriately low levels of circulating parathyroid hormone. Patients with hypoparathyroidism receiving standard-of-care therapy report debilitating physical and cognitive symptoms, which may indicate a reduced health-related quality of life. The purpose of this study was to develop a new disease-specific measure of the signs and symptoms of hypoparathyroidism, the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom), and provide evidence for the content validity of items in the measure based on rigorous qualitative research methodologies for patient-reported outcome development.
METHODS
Semi-structured, individual concept elicitation interviews were conducted with five clinical experts and 42 adults with hypoparathyroidism in the USA to identify the signs and symptoms of relevance and importance to those with the condition. Transcripts were coded and analyzed using an adapted grounded theory approach. Following item generation, cognitive debriefing interviews of the draft measure were conducted in an independent sample of 16 adults with hypoparathyroidism.
RESULTS
One hundred percent of the concept elicitation patient sample reported experiencing physical symptoms that were attributed to hypoparathyroidism, including tingling/numbness/paresthesia (n = 37, 88%), muscle cramping (n = 36, 86%), and physical fatigue (n = 35, 83%). The majority of patients (n = 36, 86%) further reported experiencing cognitive dysfunction, including impaired memory (n = 24, 57%), impaired ability to have a conversation (n = 21, 50%), and lack of concentration/focus (n = 18, 43%). Seventeen major signs and symptoms were identified during item generation and included in the preliminary measure. After the cognitive debriefing, the 17-item HPES-Symptom was generated.
CONCLUSIONS
The findings provided evidence of content validity for the HPES-Symptom in US adults with hypoparathyroidism. Additional research is needed to validate the measure in patients with hypoparathyroidism to assess its psychometric properties.
Identifiants
pubmed: 31552607
doi: 10.1007/s40271-019-00388-5
pii: 10.1007/s40271-019-00388-5
pmc: PMC7075823
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
151-162Références
N Engl J Med. 2008 Jul 24;359(4):391-403
pubmed: 18650515
Qual Life Res. 2010 Oct;19(8):1087-96
pubmed: 20512662
Bone. 2019 Mar;120:535-541
pubmed: 30243992
Metabolism. 1976 Aug;25(8):909-55
pubmed: 181659
Endocrine. 2017 Oct;58(1):14-20
pubmed: 28822059
Eur J Endocrinol. 2002 Feb;146(2):215-22
pubmed: 11834431
Value Health. 2011 Dec;14(8):967-77
pubmed: 22152165
J Bone Miner Res. 2011 Oct;26(10):2317-37
pubmed: 21812031
Endocrine. 2018 Feb;59(2):237-238
pubmed: 29181618
J Clin Immunol. 2015 Jul;35(5):463-78
pubmed: 26141571
J Bone Miner Res. 2016 Jul;31(7):1440-8
pubmed: 26865527
Expert Rev Endocrinol Metab. 2015 Jan 1;10(1):5-13
pubmed: 25705243
Value Health. 2011 Dec;14(8):978-88
pubmed: 22152166
J Pediatr. 1991 Feb;118(2):220-5
pubmed: 1993948
Bull Math Biol. 2000 Jan;62(1):163-88
pubmed: 10824426
Qual Life Res. 2009 Nov;18(9):1263-78
pubmed: 19784865
J Clin Endocrinol Metab. 2016 Jul;101(7):2742-50
pubmed: 27144931
J Bone Miner Res. 2001 Oct;16(10):1846-53
pubmed: 11585349
J Endocrinol Invest. 2013 Dec;36(11):1121-7
pubmed: 24445125
J Adv Nurs. 2000 Jun;31(6):1476-84
pubmed: 10849161
Nat Rev Dis Primers. 2017 Oct 05;3:17080
pubmed: 28980621
Endocr Pract. 2014 Jul;20(7):671-9
pubmed: 24449664
J Clin Endocrinol Metab. 2016 Jun;101(6):2284-99
pubmed: 26943720
Qual Soc Work. 2016 Jan;15(1):118-133
pubmed: 26811696
Patient Relat Outcome Meas. 2019 Jan 29;10:25-36
pubmed: 30774490
Osteoporos Int. 2014 Jun;25(6):1717-26
pubmed: 24687385
Eur J Endocrinol. 2013 May 07;168(6):895-903
pubmed: 23482593
Bone. 2019 Mar;120:542-547
pubmed: 30261328
J Endocrinol Invest. 1979 Jul-Sep;2(3):267-70
pubmed: 231063
J Clin Endocrinol Metab. 2016 Aug;101(8):3045-53
pubmed: 27186861
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633